Study guide

6.1 Chronic Kidney Disease: KDIGO Guidelines & SGLT2i/nsMRA Care

Board Certified Ambulatory Care Pharmacist BCACP

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview & Patient Care Process

1.1 BCACP Exam Logistics, Blueprint & Pass Standards 1.2 The Pharmacists' Patient Care Process (PPCP) in Ambulatory Care 1.3 Communication, Health Literacy & Cultural Competence

2 Chapter 2: Cardiovascular I: Hypertension & Dyslipidemia

2.1 Hypertension Guidelines, Staging & Primary Regimens 2.2 Resistant Hypertension, Secondary Causes & Special Populations 2.3 Dyslipidemia: Statin Benefit Groups & Non-Statin Add-ons

3 Chapter 3: Cardiovascular II: Heart Failure, CAD & Anticoagulation

3.1 Heart Failure GDMT: HFrEF Four Pillars & HFpEF Management 3.2 Chronic Coronary Disease & Antiplatelet Strategies 3.3 Anticoagulation: Atrial Fibrillation, VTE & Peri-Procedural Care

4 Chapter 4: Endocrine & Metabolic Disorders

4.1 Type 2 Diabetes: Incretins, SGLT2i & Comorbidity Alignment 4.2 Advanced Diabetes: Insulin Regimens, CGM & Hypoglycemia 4.3 Thyroid & Adrenal Disorders in Ambulatory Care 4.4 Osteoporosis Screening, Prevention & Therapeutic Sequencing

5 Chapter 5: Respiratory Care & Pulmonology

5.1 Asthma Management: GINA/NAEPP Stepwise & SMART Therapy 5.2 COPD Management: GOLD Guidelines & Exacerbation Prevention 5.3 Inhalation Devices, Delivery Techniques & Patient Counseling

6 Chapter 6: Renal, Urological & Reproductive Health

6.1 Chronic Kidney Disease: KDIGO Guidelines & SGLT2i/nsMRA Care 6.2 Benign Prostatic Hyperplasia & Erectile Dysfunction 6.3 Women's Health: Contraception, Menopause & Teratogenicity

7 Chapter 7: Neuropsychiatry & Behavioral Health

7.1 Major Depressive Disorder & Anxiety Disorders 7.2 Bipolar Disorder & Schizophrenia Spectrum 7.3 Epilepsy & Movement Disorders (Parkinson's Disease) 7.4 Migraine Prevention, Acute Treatment & Headache Disorders

8 Chapter 8: Pain Management & Rheumatology

8.1 Chronic Pain, Opioid Stewardship & SUD Management 8.2 Osteoarthritis, Gout & Hyperuricemia 8.3 Rheumatoid Arthritis & Autoimmune Pharmacotherapy

9 Chapter 9: Infectious Diseases & Immunizations

9.1 Ambulatory Infections & Outpatient Antimicrobial Stewardship 9.2 HIV Pharmacotherapy, PrEP/PEP & Viral Hepatitis 9.3 Adult Immunization Schedules & ACIP Recommendations 9.4 Immunizations in Special & High-Risk Populations

10 Chapter 10: Geriatrics, Drug Interactions & Medication Safety

10.1 Geriatric Pharmacotherapy, Beers Criteria & Deprescribing 10.2 Drug Interactions, CYP450, P-gp & Transporters 10.3 Adverse Drug Events, High-Alert Medications & ISMP Safety

11 Chapter 11: Biostatistics, Study Design & Literature Evaluation

11.1 Biostatistical Principles, Hypothesis Testing & Power 11.2 Clinical Study Designs, Bias & Evidence Appraisal 11.3 Pharmacoeconomics: ICER, QALY & Value Metrics

12 Chapter 12: Practice Advancement, Quality & Healthcare Delivery

12.1 Collaborative Practice Agreements & Telehealth Practice 12.2 Quality Improvement, HEDIS & CMS Star Ratings 12.3 Care Transitions, Medication Reconciliation & SDOH 12.4 CMM Services, CPT Coding (99605-99607) & Practice Management 12.5 Clinical Ethics, Patient Advocacy & Conflicts of Interest

6.1 Chronic Kidney Disease: KDIGO Guidelines & SGLT2i/nsMRA Care

Key Takeaways Explain This Topic AI

KDIGO CKD classification utilizes a 2-dimensional CGA grid (Cause, GFR G1–G5, Albuminuria A1–A3), where urine albumin-to-creatinine ratio (UACR) ≥300 mg/g (A3) or diabetes with UACR ≥30 mg/g (A2) mandates first-line ACE inhibitor or ARB titration to maximum tolerated doses.

Standardized office systolic blood pressure (SBP) target for non-dialysis CKD is <120 mmHg per KDIGO clinical practice guidelines when tolerated, with an acceptable acute increase in serum creatinine of up to 30% after initiating or titrating RAAS inhibitors reflecting benign intraglomerular hemodynamic adjustment.

SGLT2 inhibitors (dapagliflozin, empagliflozin, canagliflozin) provide foundational nephroprotection and cardiovascular risk reduction for CKD with eGFR ≥20 mL/min/1.73m² (or UACR ≥200 mg/g), and once initiated should be continued until kidney replacement therapy despite progressive eGFR decline.

The non-steroidal mineralocorticoid receptor antagonist finerenone reduces renal and cardiovascular events in patients with T2D and CKD on maximal ACEi/ARB (initiate 10–20 mg daily if baseline eGFR ≥25 mL/min/1.73m² and serum potassium ≤4.8 mEq/L; hold if K+ >5.5 mEq/L).

CKD complication management requires strict parameters: iron repletion targeting TSAT ≥20% and ferritin ≥100 ng/mL before starting ESAs (initiated only when Hgb <10 g/dL, target 10–11 g/dL), mealtime phosphate binders (elemental calcium limit ≤1,500 mg/day; non-calcium agents like sevelamer, lanthanum, sucroferric oxyhydroxide), and novel potassium binders (patiromer, sodium zirconium cyclosilicate) to maintain RAAS inhibitor optimization.

Last updated: September 2026

Chronic Kidney Disease: KDIGO Guidelines & SGLT2i/nsMRA Care

Executive Summary: Chronic Kidney Disease (CKD) affects over 10% of the global adult population and represents a major multiplier of cardiovascular morbidity, all-cause mortality, and progression to end-stage kidney disease (ESKD). For the Board Certified Ambulatory Care Pharmacist (BCACP), mastering the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines requires deep command of 2-dimensional CGA staging, intensive blood pressure control (<120 mmHg standardized SBP), foundational renin-angiotensin-aldosterone system (RAAS) blockade, the paradigm-shifting application of sodium-glucose cotransporter 2 (SGLT2) inhibitors and non-steroidal mineralocorticoid receptor antagonists (nsMRAs), and the precise correction of downstream mineral, electrolyte, and hematologic complications.

1. KDIGO Definition, Diagnostic Criteria & 2-Dimensional CGA Staging Heatmap

Under KDIGO guidelines, Chronic Kidney Disease (CKD) is defined as abnormalities of kidney structure or function persisting for greater than 3 months with implications for health. A diagnosis requires either:

Decreased Glomerular Filtration Rate (GFR): eGFR < 60 mL/min/1.73m² for > 3 months.

Markers of Kidney Damage (one or more):

Albuminuria (Urinary Albumin-to-Creatinine Ratio [UACR] ≥ 30 mg/g or ≥ 3 mg/mmol).

Urine sediment abnormalities (e.g., dysmorphic RBCs, RBC casts, WBC casts, tubular epithelial casts).

Electrolyte and other abnormalities due to tubular disorders (e.g., renal tubular acidosis, nephrogenic diabetes insipidus).

Histological abnormalities detected on renal biopsy.

Structural abnormalities detected by imaging (e.g., polycystic kidneys, renal artery stenosis, hydronephrosis, solitary kidney).

History of kidney transplantation.

The CGA Staging Framework

KDIGO classifies CKD based on CGA : C ause (etiology such as diabetic nephropathy, hypertensive glomerulosclerosis, glomerulonephritis, polycystic kidney disease), G FR category (G1 to G5), and A lbuminuria category (A1 to A3).

  • GFR Category eGFR Range (mL/min/1.73m²) Clinical Description
  • G1 ≥ 90 Normal or high kidney function (CKD diagnosed only if structural/albuminuria marker present)
  • G2 60–89 Mildly decreased kidney function (related to normal aging if no kidney damage marker)
  • G3a 45–59 Mildly to moderately decreased kidney function
  • G3b 30–44 Moderately to severely decreased kidney function
  • G4 15–29 Severely decreased kidney function (prepare for kidney replacement therapy / vascular access)
  • G5 < 15 Kidney failure / End-Stage Kidney Disease (ESKD) (dialysis-dependent or non-dialysis)
  • Albuminuria Category UACR (mg/g) UACR (mg/mmol) 24-Hour Urine Protein (mg/24h) Clinical Classification
  • A1 < 30 < 3 < 150 Normal to mildly increased
  • A2 30–300 3–30 150–500 Moderately increased (microalbuminuria)
  • A3 > 300 > 30 > 500 Severely increased (macroalbuminuria / nephrotic if > 2200 mg/g)
  • The KDIGO Prognostic Heatmap & Monitoring Frequency

The intersection of GFR and Albuminuria categories dictates composite clinical risk (progression to kidney failure, acute kidney injury [AKI], cardiovascular hospitalization, and all-cause mortality):

Low Risk (Green / Stage G1-G2 with A1): Screen/monitor annually.

Moderate Risk (Yellow / Stage G3a-A1 or G1-G2 with A2): Reassess eGFR and UACR at least once yearly.

High Risk (Orange / Stage G3b-A1, G3a-A2, or G1-G2 with A3): Monitor eGFR and UACR 2 times per year.

Very High Risk (Red / Stage G4-G5 or G3b-A2, G3a-A3, G3b-A3): Monitor eGFR, UACR, and electrolytes 3 to 4+ times per year; refer promptly to nephrology.

  • 2. Blood Pressure Targets & Renin-Angiotensin-Aldosterone System (RAAS) Inhibition
  • Standardized Blood Pressure Targets in Non-Dialysis CKD

Blood pressure control slows renal function loss and mitigates excessive cardiovascular risk. The KDIGO Clinical Practice Guideline for Blood Pressure in CKD recommends:

Target Standardized SBP: < 120 mmHg

Standardized Measurement Requirement: This intensive target is derived from the SPRINT trial (CKD Subgroup) and applies only when blood pressure is measured using standardized, automated office blood pressure (AOBP) techniques in seated patients after 5 minutes of quiet rest. Casual or non-standardized auscultatory readings should not be titrated to < 120 mmHg due to risks of orthostatic syncope, fall-related injuries, and acute hypoperfusion.

Clinical Caveats: A less intensive target (< 130/80 mmHg) is appropriate in very elderly or frail patients, those with advanced Stage 4–5 CKD, symptomatic orthostatic hypotension, or severe baseline autonomic dysfunction.

First-Line RAAS Blockade: ACE Inhibitors & ARBs

Angiotensin-converting enzyme inhibitors (ACEis) and Angiotensin II Receptor Blockers (ARBs) reduce intraglomerular hydrostatic capillary pressure by preferentially dilating the efferent arteriole , thereby decreasing glomerular hyperfiltration, wall tension, and proteinuria. +---------------------------------------------------------------------------------------+

  • | INDICATIONS FOR FIRST-LINE ACE INHIBITOR OR ARB THERAPY |
  • +------------------------------------+--------------------------------------------------+
  • | Clinical Patient Phenotype | Guideline Recommendation Level |
  • +------------------------------------+--------------------------------------------------+
  • | CKD with Albuminuria A3 | Strong Recommendation (Grade 1B) |
  • | (UACR >300 mg/g) without Diabetes | (Titrate to highest approved/tolerated dose) |
  • +------------------------------------+--------------------------------------------------+
  • | CKD with Albuminuria A2 | Strong Recommendation (Grade 1B) |
  • | (UACR 30-300 mg/g) WITH Diabetes | (Titrate to highest approved/tolerated dose) |
  • +------------------------------------+--------------------------------------------------+
  • | CKD with Albuminuria A2 | Conditional Recommendation (Grade 2C) |
  • | (UACR 30-300 mg/g) without Diabetes| (May consider ACEi/ARB to reduce progression) |
  • +------------------------------------+--------------------------------------------------+
  • The "Permissible Dip" Rule in Serum Creatinine

Following initiation or upward titration of an ACEi or ARB, the clinician must obtain repeat serum creatinine (SCr), eGFR, and serum potassium in 2 to 4 weeks :

Acceptable Hemodynamic Effect: A rise in serum creatinine of up to 30% from baseline (or a corresponding decline in eGFR up to 30%) is an expected, reversible consequence of reduced intraglomerular pressure and correlates with long-term preservation of renal parenchyma . Do NOT reduce the dose or discontinue therapy.

Unacceptable Elevation (>30% rise): If SCr increases by > 30%, evaluate for volume depletion, excessive diuresis, concomitant NSAID therapy, severe renal artery stenosis (bilateral or solitary kidney), or acute obstructive uropathy. Temporarily reduce or withhold the RAAS inhibitor while correcting underlying precipitants.

Absolute Practice Warning — Dual RAAS Blockade: Combining an ACE inhibitor with an ARB or a direct renin inhibitor (aliskiren) is strictly contraindicated . Landmark randomized trials ( ONTARGET , ALTITUDE , VA NEPHRON-D ) demonstrated that dual RAAS blockade produces no additional renal or cardiovascular benefit while significantly increasing rates of hyperkalemia, acute kidney injury, and symptomatic hypotension.

3. SGLT2 Inhibitors: The Transformative Pillar of CKD Care

Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors have revolutionized nephrology, transitioning from antidiabetic agents to universal disease-modifying therapies for chronic kidney disease, regardless of diabetes status.

Pharmacodynamic Mechanism in the Nephron

Restoration of Tubuloglomerular Feedback: In diabetic and non-diabetic CKD, hyperfiltration is driven by proximal tubular sodium and glucose hyper-reabsorption. SGLT2 inhibitors block sodium-glucose cotransport in the S1 segment of the proximal convoluted tubule, delivering increased sodium chloride to the macula densa .

Afferent Arteriolar Vasoconstriction: The macula densa releases adenosine, which constricts the dilated afferent arteriole , reducing intraglomerular hypertension and attenuating structural barotrauma.

Metabolic & Anti-inflammatory Effects: Reduces renal cortical hypoxia, decreases glucotoxicity, downregulates pro-fibrotic cytokines (TGF-beta, TNF-alpha), and promotes systemic ketogenesis providing efficient cardiac/renal substrate.

Landmark Trial Evidence Summary

Trial Name Population Enrolled Interventional Agent Primary Composite Renal Outcome Key Cardiovascular Findings

CREDENCE (2019) 4,401 patients with T2D + CKD (eGFR 30–90, UACR 300–5,000 mg/g) on max ACEi/ARB Canagliflozin 100 mg daily vs placebo 30% Relative Risk Reduction (RRR) in ESKD, doubling of SCr, or renal/CV death (p=0.00001) 39% reduction in heart failure hospitalization; 20% reduction in MACE

DAPA-CKD (2020) 4,304 patients with CKD (eGFR 25–75, UACR 200–5,000 mg/g) with and without T2D Dapagliflozin 10 mg daily vs placebo 39% RRR in ≥ 50% sustained eGFR decline, ESKD, or renal/CV death (p<0.001; NNT = 19) 31% reduction in CV death or HF hospitalization; 31% reduction in all-cause mortality

EMPA-KIDNEY (2022) 6,609 patients with CKD (eGFR 20–45 without albuminuria, OR eGFR 20–90 with UACR ≥ 200) with and without T2D Empagliflozin 10 mg daily vs placebo 28% RRR in kidney disease progression or CV death (p<0.001) Consistent renal benefit across non-diabetic and normoalbuminuric CKD cohorts

KDIGO Clinical Implementation Rules for SGLT2 Inhibitors

Initiation Threshold: Initiate an SGLT2 inhibitor ( Dapagliflozin 10 mg daily , Empagliflozin 10 mg daily , or Canagliflozin 100 mg daily ) in all adults with:

Type 2 Diabetes and CKD with eGFR ≥ 20 mL/min/1.73m².

Non-diabetic CKD with eGFR ≥ 20 mL/min/1.73m² and UACR ≥ 200 mg/g (or comorbid Heart Failure with reduced/preserved ejection fraction).

The Continuation Rule (Never Stop for Low eGFR): While glycemic lowering wanes when eGFR drops < 45 mL/min/1.73m², renal and cardiovascular benefits persist down to dialysis . Once an SGLT2 inhibitor is initiated at eGFR ≥ 20, continue therapy even if eGFR falls below 20 mL/min/1.73m² , until kidney replacement therapy (dialysis or transplantation) is initiated or the drug is not tolerated.

Initial Hemodynamic eGFR "Dip": A predictable, acute decline in eGFR of 3 to 5 mL/min/1.73m² occurs within the first 2 to 4 weeks due to afferent arteriolar constriction. This is a functional marker of therapeutic hemodynamic unloading, not structural tubular damage. Long-term eGFR decline slows dramatically compared to placebo.

Safety & Adverse Event Mitigation:

Euglycemic Diabetic Ketoacidosis (euDKA): Instruct patients on sick-day rules; temporarily withhold SGLT2i at least 3 days before major elective surgery , during prolonged fasting, severe acute illness, or excessive alcohol intake.

Mycotic Genital Infections: Counsel on daily perineal hygiene and hydration; treat candida infections with topical or short-course oral antifungals without necessarily discontinuing the SGLT2i.

Volume Depletion / Hypotension: If baseline BP is low or patient is on high-dose loop diuretics, consider a modest reduction in diuretic dose prior to SGLT2i initiation.

4. Non-Steroidal Mineralocorticoid Receptor Antagonists: Finerenone

In diabetic kidney disease, persistent overactivation of the mineralocorticoid receptor (MR) drives chronic inflammation, endothelial dysfunction, and interstitial fibrosis in renal tubules and myocardium. Traditional steroidal MRAs (spironolactone, eplerenone) are limited in CKD by severe hyperkalemia and endocrine adverse effects (gynecomastia, breast pain with spironolactone).

Pharmacodynamic Profile of Finerenone

Selective Non-Steroidal Architecture: Bulky, non-steroidal structure binds the MR with high affinity and selectivity, acting as an antagonist that prevents MR cofactor recruitment without activating androgen or progesterone receptors.

Balanced Tissue Distribution: Distributes equally between renal and cardiac tissues (spironolactone has 6-fold higher renal accumulation), translating to potent anti-inflammatory and antifibrotic activity with a lower incidence of severe hyperkalemia.

Clinical Evidence: FIDELIO-DKD demonstrated an 18% RRR in composite renal outcomes (ESKD, sustained ≥ 40% eGFR decline, renal death) in T2D with CKD on maximal ACEi/ARB. FIGARO-DKD demonstrated a 13% RRR in composite cardiovascular outcomes (CV death, non-fatal MI, non-fatal stroke, HF hospitalization). The pooled FIDELITY analysis confirmed robust cardiorenal protection across early-to-late CKD stages.

Finerenone Dosing, Potassium Thresholds & Titration Algorithm +---------------------------------------------------------------------------------------+

  • | FINERENONE CLINICAL INITIATION & TITRATION PROTOCOL |
  • +------------------------------------+--------------------------------------------------+
  • | Clinical Parameter | Mandatory Clinical Rule |
  • +------------------------------------+--------------------------------------------------+
  • | Baseline Patient Eligibility | T2D + CKD (eGFR >= 25 mL/min/1.73m², UACR >= 30 |
  • | | mg/g) on maximum tolerated dose of ACEi or ARB |
  • +------------------------------------+--------------------------------------------------+
  • | Mandatory Potassium Threshold | Serum Potassium MUST be <= 4.8 mEq/L to initiate |
  • | | (If K+ > 4.8 to 5.0, optimize diet; if > 5.0, hold|
  • +------------------------------------+--------------------------------------------------+
  • | Starting Dose (eGFR >= 60) | 20 mg orally once daily |
  • +------------------------------------+--------------------------------------------------+
  • | Starting Dose (eGFR 25 to <60) | 10 mg orally once daily |
  • +------------------------------------+--------------------------------------------------+
  • | Severe CKD (eGFR < 25) | Initiation NOT recommended |
  • +------------------------------------+--------------------------------------------------+
  • | Mandatory 4-Week Monitoring | Check Serum Potassium & SCr at 4 weeks |
  • +------------------------------------+--------------------------------------------------+
  • | Titration Rule (from 10 mg daily) | If K+ <= 4.8 mEq/L and eGFR stable: Increase to |
  • | | 20 mg once daily |
  • | | If K+ 4.9 to 5.5 mEq/L: Maintain 10 mg daily |
  • | | If K+ > 5.5 mEq/L: WITHHOLD finerenone; restart |
  • | | at 10 mg daily when K+ <= 5.0 mEq/L |
  • +------------------------------------+--------------------------------------------------+

Loading diagram... KDIGO Multimodal Cardiorenal Protection Workflow in CKD & Type 2 Diabetes

5. Ambulatory Hyperkalemia Management & Novel Potassium Binders

Hyperkalemia (K+ > 5.0 mEq/L, severe if > 6.0 mEq/L) is a frequent complication in CKD exacerbated by impaired distal tubular potassium excretion, metabolic acidosis, and the use of guideline-directed medical therapy (ACEi, ARB, nsMRAs, beta-blockers). Historical practice of abruptly discontinuing life-prolonging RAAS inhibitors is associated with increased cardiovascular and renal mortality. Modern ambulatory practice pairs dietary education with non-absorbed gastrointestinal potassium binders to maintain patients on optimal RAASi/nsMRA regimens.

Historical vs. Modern Potassium Binders

Sodium Polystyrene Sulfonate (SPS / Kayexalate): Cation-exchange resin in exchange for sodium. Inefficient, unpredictable onset (hours to days), poor tolerability, high sodium burden, and carries an FDA warning for intestinal necrosis, bowel perforation, and ischemic colitis , particularly when administered with sorbitol. Not recommended for chronic ambulatory management.

Novel Cation Exchangers in Ambulatory Care

Feature Patiromer (Veltassa) Sodium Zirconium Cyclosilicate (SZC / Lokelma)

Chemical Composition Cross-linked polymer of polyfluoracrylic acid with calcium-sorbitol counterions Non-absorbed inorganic sodium zirconium silicate microporous crystalline lattice

Mechanism of Action Binds K+ in the distal colon in exchange for Ca2+ Selectively entraps K+ and NH4+ throughout the entire gastrointestinal tract in exchange for Na+ and H+

Onset of Action 4 to 7 hours (delayed; not for acute emergency) 1 to 2 hours (rapid onset; fastest oral binder)

Standard Outpatient Dosing 8.4 g powder packet once daily with food; titrate weekly by 8.4 g increments up to 25.2 g daily Acute Phase: 10 g TID with water for up to 48 hours.; Maintenance: 5 to 10 g once daily.

Electrolyte Side Effects Hypomagnesemia (binds GI magnesium; monitor Mg levels), constipation, diarrhea, flatulence Edema / Fluid Overload (each 5 g dose contains ~400 mg sodium ; use caution in severe heart failure, cirrhosis, HD)

Drug-Drug Separation Rules Separate by at least 3 hours before or 3 hours after other oral medications (binds numerous drugs) Separate by at least 2 hours before or after oral drugs with gastric pH-dependent bioavailability (e.g., azole antifungals, protease inhibitors, dabigatran)

6. Renal Function Assessment & Drug Dosing Mathematics

Precise calculation of kidney function is critical for outpatient medication safety and dose optimization. Ambulatory care pharmacists must navigate the clinical dichotomy between historical FDA-approved package inserts and contemporary nephrology guidelines.

Cockcroft-Gault Creatinine Clearance (C-G CrCl)

The Cockcroft-Gault formula (1976) estimates creatinine clearance in mL/min (unadjusted for body surface area) and remains the mandated metric in the majority of FDA-approved package inserts (e.g., direct oral anticoagulants [DOACs], antimicrobials, SGLT2i historical labels): CrCl (mL/min) = ( 140 − Age ) × Weight (kg) 72 × Serum Creatinine (mg/dL) × ( 0.85 if Female ) \text{CrCl (mL/min)} = \frac{(140 - \text{Age}) \times \text{Weight (kg)}}{72 \times \text{Serum Creatinine (mg/dL)}} \times (0.85 \text{ if Female}) CrCl (mL/min) = 72 × Serum Creatinine (mg/dL) ( 140 − Age ) × Weight (kg) ​ × ( 0.85 if Female )

Weight Selection Protocol in Cockcroft-Gault Calculations

Underweight (Actual Weight [TBW] < Ideal Body Weight [IBW]): Use Actual Body Weight (TBW) to avoid overestimating clearance. IBW (Male) = 50 kg + 2.3 kg × ( Height in inches − 60 ) \text{IBW (Male)} = 50\text{ kg} + 2.3\text{ kg} \times (\text{Height in inches} - 60) IBW (Male) = 50 kg + 2.3 kg × ( Height in inches − 60 ) IBW (Female) = 45.5 kg + 2.3 kg × ( Height in inches − 60 ) \text{IBW (Female)} = 45.5\text{ kg} + 2.3\text{ kg} \times (\text{Height in inches} - 60) IBW (Female) = 45.5 kg + 2.3 kg × ( Height in inches − 60 )

Normal Weight (TBW is 100% to 120% of IBW): Use IBW (or TBW per institutional protocol; IBW is standard on BCACP examination items).

Overweight / Obese (TBW > 120% of IBW or BMI ≥ 30 kg/m²): Use Adjusted Body Weight (AdjBW) with an adiposity correction factor of 0.4: AdjBW = IBW + 0.4 × ( TBW − IBW ) \text{AdjBW} = \text{IBW} + 0.4 \times (\text{TBW} - \text{IBW}) AdjBW = IBW + 0.4 × ( TBW − IBW )

CKD-EPI (2021 Race-Free) eGFR Equation

Expressed in mL/min/1.73m² (normalized to standard body surface area).

Recommended by KDIGO, NKF, and ASN for CKD staging, epidemiological risk estimation, and clinical trial stratification.

BSA De-Indexing for Drug Dosing: In patients with extreme body surface area (e.g., severe obesity or severe muscle wasting) receiving narrow therapeutic index drugs, de-index eGFR to mL/min before dosing: eGFR (mL/min) = eGFR (mL/min / 1.73 m 2 ) × Patient BSA (m 2 ) 1.73 \text{eGFR (mL/min)} = \text{eGFR (mL/min}/1.73\text{m}^2) \times \frac{\text{Patient BSA (m}^2)}{1.73} eGFR (mL/min) = eGFR (mL/min /1.73 m 2 ) × 1.73 Patient BSA (m 2 ) ​

Board Exam Decision Rule: For medications with strict FDA boxed warnings and renal dosing cutoffs based on Cockcroft-Gault (such as apixaban , rivaroxaban , edoxaban , and dabigatran ), calculate and utilize Cockcroft-Gault CrCl with appropriate weight selection .

  • 7. Complications of CKD: Anemia & Mineral-Bone Disorder (CKD-MBD)
  • Anemia of Chronic Kidney Disease

Anemia of CKD is predominantly normocytic, normochromic and develops primarily from deficient erythropoietin (EPO) production by peritubular fibroblasts in the renal cortex, compounded by functional iron deficiency mediated by elevated hepcidin (which internalizes and degrades ferroportin, trapping iron in enterocytes and macrophages).

Diagnostic Workup & Iron Repletion Targets

Before initiating an Erythropoiesis-Stimulating Agent (ESA), non-renal causes of anemia (B12, folate deficiency, GI hemorrhage, hemolysis) must be ruled out and iron stores fully repleted.

Transferrin Saturation (TSAT): Target ≥ 20% (optimal 20–50%).

Serum Ferritin: Target ≥ 100 ng/mL for non-dialysis CKD; ≥ 200 ng/mL for hemodialysis-dependent CKD.

Route of Administration: Oral iron (e.g., ferrous sulfate 325 mg [65 mg elemental iron] daily to TID on empty stomach, ferric maltol) is reasonable in non-dialysis CKD. However, if TSAT remains < 20% or oral iron causes intolerable GI adverse effects, Intravenous (IV) Iron (iron sucrose, ferric gluconate, ferric carboxymaltose, ferumoxytol) is superior and mandatory in hemodialysis.

Erythropoiesis-Stimulating Agents (ESAs) & Safety Thresholds

Agents: Epoetin alfa (Epogen, Procrit: short-acting, 1–3x weekly), Darbepoetin alfa (Aranesp: hyperglycosylated, long-acting, once every 1–4 weeks), Methoxy polyethylene glycol-epoetin beta (Mircera: continuous receptor activator, q2–4 weeks).

Initiation Rule: In non-dialysis CKD, consider ESA initiation ONLY when Hemoglobin drops < 10.0 g/dL , individualizing therapy to reduce the rate of red blood cell transfusions.

Target Hemoglobin Ceiling: Maintain hemoglobin between 10.0 and 11.0 g/dL . DO NOT target hemoglobin > 11.5 g/dL (and never > 13.0 g/dL). Dose should be reduced by 25% or temporarily held if Hgb increases by > 1.0 g/dL over any 2-week period.

FDA Boxed Warning (TREAT, CHOIR, CREATE Trials): Targeting normal hemoglobin levels (> 13.0 g/dL) with ESAs in CKD causes a statistically significant increase in stroke, major adverse cardiovascular events (MI, heart failure hospitalization), venous thromboembolism, vascular access thrombosis, and all-cause mortality .

Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)

CKD-MBD is a systemic disorder characterized by biochemical abnormalities (calcium, phosphorus, PTH, FGF-23, vitamin D), bone histology defects (renal osteodystrophy), and vascular/valvular soft tissue calcification. CKD-MBD PATHOPHYSIOLOGIC CASCADE

  • Loss of Functional Nephrons (Stage 3-5 CKD)
  • │
  • ├──> 1. Decreased Phosphate Excretion ──> HYPERPHOSPHATEMIA
  • │ │
  • ├──> 2. Loss of 1α-Hydroxylase (CYP27B1) ├──> Binds Free Calcium
  • │ │ │ │
  • │ ▼ │ ▼
  • │ Decreased 1,25-(OH)2-D (Calcitriol) │ HYPOCALCEMIA
  • │ │ │ │
  • │ ▼ │ │
  • │ Decreased Intestinal Ca2+ Absorption ──────┤ │
  • │ ▼
  • └──> 3. Osteocytes Secrete FGF-23 ──────────> SECONDARY HYPERPARATHYROIDISM
  • │
  • ▼
  • Renal Osteodystrophy & Vascular Calcification
  • 1. Dietary Phosphorus Restriction

Initial management in Stage 3–5 CKD involves restricting dietary phosphate to 800 to 1,000 mg/day by limiting processed foods, sodas, dairy, and inorganic phosphate preservatives.

2. Phosphate Binders (MUST Be Taken WITH MEALS)

Phosphate binders bind dietary phosphorus in the intestinal lumen, forming insoluble complexes excreted in feces. They are ineffective if taken between meals.

Binder Category Drug Name & Brand Mechanism & Dosing Advantages & Clinical Pearls Key Adverse Effects & Caveats

Calcium-Based Binders Calcium Acetate (PhosLo: 667 mg/tab, 169 mg elemental Ca); Calcium Carbonate (Tums: 500 mg tab, 200 mg elemental Ca) Cation exchange forming insoluble calcium phosphate Inexpensive; calcium acetate binds twice as much phosphate per gram of calcium as carbonate Hypercalcemia & accelerated vascular calcification . Limit total elemental calcium from binders to ≤ 1,500 mg/day (total daily intake ≤ 2,000 mg/day)

Non-Calcium Polymeric Sevelamer Carbonate (Renvela: 800 mg TID); Sevelamer HCl (Renagel) Non-absorbed cross-linked polymer amine that binds phosphate via ion exchange Avoids calcium load; lowers LDL-C by 15–30% by binding bile acids; carbonate form treats metabolic acidosis Severe GI upset (nausea, constipation, vomiting, bowel obstruction); high pill burden

Rare Earth Heavy Metal Lanthanum Carbonate (Fosrenol: 500–1000 mg TID with meals) Rare earth element that dissociates in acidic stomach, binding phosphate in duodenum Potent binding; chewable tablets; low pill volume Must chew thoroughly before swallowing (unchewed tabs cause severe esophageal/GI impaction); radiopaque on X-rays

Iron-Based Binders Sucroferric Oxyhydroxide (Velphoro: 500 mg TID with meals); Ferric Citrate (Auryxia: 210 mg ferric iron/tab, 2 tabs TID) Polynuclear iron(III)-oxyhydroxide binding phosphate Low pill burden (Velphoro); Auryxia increases ferritin/TSAT , treating concomitant anemia and reducing IV iron/ESA requirements Discolored dark/black stools; Velphoro chewable must not be swallowed whole

3. Vitamin D & Vitamin D Receptor Activators (VDRAs)

Nutritional Vitamin D (Ergocalciferol D2, Cholecalciferol D3): Used in Stage 3–4 CKD if 25-hydroxyvitamin D is deficient (< 30 ng/mL). Ineffective at suppressing PTH in Stage 5 CKD due to lack of functional 1α-hydroxylase.

Active Vitamin D (Calcitriol [1,25-(OH)2D3], Rocaltrol) & Selective VDRAs (Paricalcitol [Zemplar], Doxercalciferol [Hectorol]): Directly bind the parathyroid VDR to suppress PTH gene transcription. Paricalcitol has lower calcemic and phosphatemic activity than calcitriol, reducing hypercalcemia risk.

4. Calcimimetics

Cinacalcet (Sensipar: 30 to 180 mg once daily with food): Allosteric activator of the Calcium-Sensing Receptor (CaSR) on the parathyroid gland. Increases the CaSR sensitivity to extracellular calcium, thereby suppressing PTH without increasing serum calcium or phosphorus (in fact, it lowers Ca and P).

Mandatory Monitoring: Hypocalcemia risk . Do NOT initiate cinacalcet if baseline serum calcium (corrected for albumin) is < 8.4 mg/dL. Check calcium within 1 week of initiation or dose titration; frequent nausea/vomiting.

Etelcalcetide (Parsabiv): Intravenous calcimimetic administered 3 times weekly at the end of hemodialysis sessions.